文献速递泌尿生殖与妇科肿瘤放疗

CHHiP试验中比卡鲁胺与促黄体生成素释放激素类似物联合放疗的非随机疗效与不良反应比较

Nonrandomized Comparison of Efficacy and Side Effects of Bicalutamide Compared With Luteinizing Hormone-Releasing Hormone (LHRH) Analogs in Combination With Radiation Therapy in the CHHiP Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2022-01-10

CHHiP试验中97%参与者接受短程激素治疗(LHRHa或比卡鲁胺150mg/日),本探索性非随机比较纳入2700例LHRHa与403例比卡鲁胺患者,中位随访9.3年,两组生化/临床失败无差异(校正HR 0.97,95%CI 0.77-1.23,P=0.8);2年时LHRHa组临床医生评估的LENT-SOM勃起功能障碍(ED)≥2级显著更多(53% vs 25%,P<0.0001),但患者报告结局问卷无差异。

要点

  • 比卡鲁胺组与LHRHa组生化/临床失败无差异,校正HR 0.97(95%CI 0.77-1.23,P=0.8)。
  • 2年时LENT-SOM评估的≥2级ED在LHRHa组为53%(313/590),比卡鲁胺组为25%(17/68),P<0.0001。
  • UCLA-PCI与EPIC-50问卷评估的ED在两组间无差异。

核心结论

  • 在非随机比较中,未发现因激素治疗类型不同而导致疗效差异的证据。
  • 比卡鲁胺在2年时保留了临床医生评估(LENT-SOM)的勃起功能,但患者报告结局两组相似。

研究设计与样本

  • CHHiP试验的探索性非随机比较,比较比卡鲁胺与LHRHa联合放疗的疗效与不良反应。
  • 2700例患者接受LHRHa,403例接受比卡鲁胺。
  • 主要终点为生化/临床失败,采用Cox回归校正多种预后因素并按放疗剂量分层。

主要发现

  • 比卡鲁胺组患者显著更年轻(中位67岁 vs LHRHa组69岁)。
  • 中位随访9.3年,生化或临床失败无差异,校正风险比0.97(95%CI 0.77-1.23;P=0.8)。
  • 2年时LENT-SOM≥2级ED在LHRHa组为53%(313/590),显著高于比卡鲁胺组的25%(17/68)(P<0.0001)。
  • UCLA-PCI和EPIC-50问卷评估的ED无差异。

关键数值与推荐

  • 主要终点生化/临床失败:校正HR 0.97(95%CI 0.77-1.23;P=0.8)。
  • 2年LENT-SOM≥2级ED:LHRHa组53%(313/590)vs 比卡鲁胺组25%(17/68),P<0.0001。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: CHHiP is a randomized trial evaluating moderately hypofractionated radiation therapy for treatment of localized prostate cancer. Of all participants, 97% of them had concurrent short-course hormone therapy (HT), either luteinizing hormone-releasing hormone analog (LHRHa) or 150 mg of bicalutamide daily. This exploratory analysis compares efficacy and side effects in a nonrandomized comparison. METHODS AND MATERIALS: In our study, 2700 patients received LHRHa and 403 received bicalutamide. The primary endpoint was biochemical/clinical failure. Groups were compared with Cox regression adjusted for various prognostic factors and stratified by radiation therapy dose. A key secondary endpoint was erectile dysfunction (ED) assessed by clinicians (using scores from Late Effects on Normal Tissues: Subjective/Objective/Management [LENT-SOM] subjective erectile function for vaginal penetration) and patients (single items within the University of California-Los Angeles Prostate Cancer Index [UCLA PCI] and Expanded Prostate Cancer Index Composite [EPIC]-50 questionnaires) at 2 years and compared between HT regimens by χ2 trend test. RESULTS: Bicalutamide patients were significantly younger (median 67 vs 69 years LHRHa). Median follow-up was 9.3 years. There was no difference in biochemical or clinical failure with an adjusted hazard ratio or 0.97 (95% confidence interval, 0.77-1.23; P = .8). At 2 years, grade ≥2 LENT-SOM ED was reported in significantly more LHRHa patients (313 out of 590; 53%) versus bicalutamide (17 out of 68; 25%) (P < .0001). There were no differences in ED seen with UCLA-PCI and EPIC-50 questionnaires. CONCLUSIONS: In this nonrandomized comparison, there was no evidence of a difference in efficacy according to type of HT received. Bicalutamide preserved clinician assessed (LENT-SOM) erectile function at 2 years but patient-reported outcomes were similar between groups.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Tree A, Griffin C, Syndikus I, et al. Nonrandomized Comparison of Efficacy and Side Effects of Bicalutamide Compared With Luteinizing Hormone-Releasing Hormone (LHRH) Analogs in Combination With Radiation Therapy in the CHHiP Trial. Int J Radiat Oncol Biol Phys. 2022. PMID: 35017008. doi:10.1016/j.ijrobp.2021.12.160

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。